Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis

Not Applicable

• Conditions: Systemic Sclerosis
• Interventions: Other: Blood test

• Registration Number: NCT01943968
• Lead Sponsor: Hillel Yaffe Medical Center

Brief Summary

The aim of our study is to find a biomarker for fibrosis or vasculopathy in systemic sclerosis. We will evaluate a possible correlation between semaphorin 7a, semaphorin 3a and lysyl oxidase and fibrosis (lung and skin) or vasculopathy in patients with systemic sclerosis. The results obtained may help us diagnose these complications of systemic sclerosis and hopefully even monitor patient treatment.

Detailed Description

Not available

Study Timeline

• Status Verified: 2013-09
• Study First Submitted: 2013-09-12
• Study First Submitted QC: 2013-09-12
• Last Update Submitted: 2013-09-12
• Study First Posted: 2013-09-17
• Last Update Posted: 2013-09-17
• Study Start: 2013-12
• Primary Completion: 2014-06
• Study Completion: 2014-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Systemic Sclerosis Patients
• Written consent to participation in study

Exclusion Criteria

• Serious active medical condition
• Other autoimmune rheumatic disease
• Current or past allergic/inflammatory reaction
• Liver disease
• Pregnant or breastfeeding
• Illegal drug or alcohol abuse

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Systemic sclerosis patients	Blood test	Systemic sclerosis patients will have blood tested for fibrotic enzyme levels

Primary Outcome Measures

Name	Time	Method
Fibrin Enzyme Levels in Blood	Six months	Patients will undergo blood tests before study and after six months to determine levels of lysyl oxidase, semaphorin 7a and 3a and thus determine severity of the disease (systemic sclerosis).

Trial Locations

Locations (1)

Bnai Zion Medical Center; 🇮🇱 Haifa, Israel